INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Purchases 7,690 Shares of Stock

INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss bought 7,690 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average price of $6.38 per share, with a total value of $49,062.20. Following the transaction, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at $8,140,044.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

INmune Bio Stock Performance

Shares of NASDAQ INMB opened at $5.39 on Tuesday. INmune Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $14.74. The stock has a market cap of $106.53 million, a PE ratio of -2.80 and a beta of 1.86. The stock has a fifty day moving average of $7.39 and a 200-day moving average of $9.19.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Analyst Upgrades and Downgrades

Separately, Scotiabank initiated coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective for the company.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers bought a new position in INmune Bio in the 2nd quarter valued at $121,000. Financial Advocates Investment Management boosted its stake in INmune Bio by 8.6% during the fourth quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock valued at $141,000 after buying an additional 990 shares during the period. Fermata Advisors LLC grew its position in INmune Bio by 8.5% during the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after buying an additional 2,689 shares in the last quarter. Westside Investment Management Inc. increased its stake in INmune Bio by 31.8% in the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after acquiring an additional 10,950 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.